Recently, the Global Alliance for Cannabis Commerce (GACC) and Law Enforcement Action Partnership (LEAP) sent a letter to Senate Majority Leader Chuck Schumer (D-NY) expressing their support for streamlining cannabis research.
The organizations argue that the Medical Marijuana and Cannabidiol Research Expansion Act “does not expand research into existing cannabis medicines and only permits research for the purpose of a pharmaceutical New Drug Application (NDA) by large pharmaceutical companies.”
